Searched for
DONANEMAB CLINICAL STUDY
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...- India is well positioned to attract future investments, says Eli Lilly's Patrik JonssonEli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for data pro...
- India is well positioned to attract future investments: Patrik Jonsson, President, Lilly InternationalEli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for stronger...
- India clinical trial to evaluate efficacy of glutathione therapy for early Alzheimer's DiseaseTitled "Impact of Glutathione (GSH) Supplementation in Mild Cognitive Impairment (MCI) Patients: A Randomized Control Trial", the study is ...
- Roche's Alzheimer's drug fails to meet goal in long awaited trialRoche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and E...
- World Alzheimer’s Day: 45 mins of daily exercise, 7-8 hrs of sleep, protein-rich diet can keep disease at bayAir pollution and other environmental factors can also speed up the onset of Azhiemer’s disease.
Load More